Shares of Novo Nordisk ( NVO +3.42%) are gaining on Monday, up 3.5% as of 2:40 p.m. ET. The jump comes as the S&P 500 and the Nasdaq Composite gained 0.8% and 0.9%, respectively. The Danish drugmaker ...

Data from the Evoke trials suggests that GLP-1 drugs that treat type 2 diabetes do not have a significant effect on Alzheimer ...

Medicare will save approximately 44%, on 15 high-cost medications as a result of the second round of the program’s drug price ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

How drugs were selected: Drugs were selected earlier this year based on criteria written into the law. They had to have no ...

Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include ...

Through the FDA’s priority voucher program, Novo Nordisk said Nov. 26 it has filed an application seeking approval of its Wegovy 7.2 milligram injection.  Wegovy (semaglutide) is currently approved in ...

Europe's main equity indexes closed higher on Wednesday, led by technology stocks as growing expectations of a U.S. rate cut ...

The Trump administration late Tuesday announced new lower Medicare prices for 15 drugs that were part of the latest round of the program’s price negotiations, touting a total of $12 billion ...

The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review ...

On a more positive note, Novo Nordisk reported positive results from a Phase 2 trial of its next highly promising GLP-1 ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...